$32.26 Million in Sales Expected for Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) This Quarter

Brokerages expect Intra-Cellular Therapies, Inc. (NASDAQ:ITCIGet Rating) to report $32.26 million in sales for the current quarter, according to Zacks Investment Research. Three analysts have made estimates for Intra-Cellular Therapies’ earnings. The highest sales estimate is $32.50 million and the lowest is $32.08 million. Intra-Cellular Therapies reported sales of $15.88 million in the same quarter last year, which would suggest a positive year-over-year growth rate of 103.1%. The company is expected to issue its next earnings results on Monday, January 1st.

On average, analysts expect that Intra-Cellular Therapies will report full year sales of $196.31 million for the current year, with estimates ranging from $192.93 million to $202.00 million. For the next fiscal year, analysts expect that the firm will post sales of $422.28 million, with estimates ranging from $376.90 million to $483.95 million. Zacks’ sales averages are a mean average based on a survey of research analysts that cover Intra-Cellular Therapies.

Intra-Cellular Therapies (NASDAQ:ITCIGet Rating) last issued its quarterly earnings data on Tuesday, March 1st. The biopharmaceutical company reported ($1.05) EPS for the quarter, hitting the Thomson Reuters’ consensus estimate of ($1.05). Intra-Cellular Therapies had a negative net margin of 339.04% and a negative return on equity of 54.89%. The business had revenue of $25.67 million during the quarter, compared to analyst estimates of $24.93 million. During the same period last year, the business posted ($0.76) earnings per share. Intra-Cellular Therapies’s quarterly revenue was up 106.1% compared to the same quarter last year.

A number of equities research analysts have recently issued reports on the stock. Zacks Investment Research raised shares of Intra-Cellular Therapies from a “sell” rating to a “hold” rating in a research report on Thursday, January 13th. StockNews.com initiated coverage on shares of Intra-Cellular Therapies in a research note on Thursday, March 31st. They issued a “sell” rating on the stock. SVB Leerink boosted their price target on shares of Intra-Cellular Therapies from $50.00 to $65.00 and gave the stock an “outperform” rating in a research note on Wednesday, March 2nd. The Goldman Sachs Group initiated coverage on shares of Intra-Cellular Therapies in a research note on Wednesday, February 16th. They issued a “buy” rating and a $64.00 price target on the stock. Finally, Royal Bank of Canada upped their target price on shares of Intra-Cellular Therapies from $50.00 to $55.00 and gave the company an “outperform” rating in a research report on Tuesday, December 21st. One analyst has rated the stock with a sell rating, one has assigned a hold rating and six have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average target price of $59.83.

In other news, EVP Mark Neumann sold 86,348 shares of the stock in a transaction that occurred on Friday, April 8th. The shares were sold at an average price of $64.37, for a total transaction of $5,558,220.76. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Suresh K. Durgam sold 6,223 shares of the stock in a transaction that occurred on Tuesday, January 18th. The shares were sold at an average price of $42.03, for a total transaction of $261,552.69. The disclosure for this sale can be found here. Insiders sold a total of 286,380 shares of company stock worth $16,785,814 over the last 90 days. Insiders own 13.20% of the company’s stock.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Profund Advisors LLC boosted its stake in shares of Intra-Cellular Therapies by 4.2% during the fourth quarter. Profund Advisors LLC now owns 7,040 shares of the biopharmaceutical company’s stock valued at $368,000 after purchasing an additional 283 shares in the last quarter. State Board of Administration of Florida Retirement System lifted its position in Intra-Cellular Therapies by 1.1% during the fourth quarter. State Board of Administration of Florida Retirement System now owns 27,546 shares of the biopharmaceutical company’s stock valued at $1,442,000 after acquiring an additional 293 shares during the last quarter. LPL Financial LLC lifted its position in Intra-Cellular Therapies by 2.7% during the third quarter. LPL Financial LLC now owns 14,917 shares of the biopharmaceutical company’s stock valued at $556,000 after acquiring an additional 391 shares during the last quarter. ProShare Advisors LLC lifted its position in Intra-Cellular Therapies by 1.8% during the fourth quarter. ProShare Advisors LLC now owns 26,913 shares of the biopharmaceutical company’s stock valued at $1,408,000 after acquiring an additional 476 shares during the last quarter. Finally, Advisor Group Holdings Inc. lifted its position in Intra-Cellular Therapies by 63.3% during the fourth quarter. Advisor Group Holdings Inc. now owns 1,568 shares of the biopharmaceutical company’s stock valued at $82,000 after acquiring an additional 608 shares during the last quarter. Hedge funds and other institutional investors own 83.48% of the company’s stock.

Shares of NASDAQ ITCI opened at $64.70 on Thursday. Intra-Cellular Therapies has a twelve month low of $28.40 and a twelve month high of $66.00. The firm has a market cap of $6.06 billion, a P/E ratio of -18.49 and a beta of 1.20. The company has a 50 day moving average of $57.91 and a 200 day moving average of $47.86.

Intra-Cellular Therapies Company Profile (Get Rating)

Intra-Cellular Therapies, Inc, a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults.

See Also

Get a free copy of the Zacks research report on Intra-Cellular Therapies (ITCI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Intra-Cellular Therapies (NASDAQ:ITCI)

Receive News & Ratings for Intra-Cellular Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intra-Cellular Therapies and related companies with MarketBeat.com's FREE daily email newsletter.